CB-238,618

· Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CB-238,618, covering 2019-02-18 to 2019-02-18. Get the full timeline:

Most recent: Clinical Trial Update: Study of Pharmacokinetics of a Single IV Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects (MK-6183-001) [Phase 1]

See pricing